StockNow
Calendar
Log in
Other

Novo Nordisk (NOVOB DC/NVO) to present new CagriSema and Wegovy data at ObesityWeek 2026, including data on real-world treatment experience with the Wegovy pill

ORIGINAL · NewsquawkNovo Nordisk (NOVOB DC/NVO) to present new CagriSema and Wegovy data at ObesityWeek 2026, including data on real-world treatment experience with the Wegovy pill
StockNow breaking-news AI analysis

Novo announced planned ObesityWeek 2026 presentations on CagriSema and Wegovy, including Wegovy-pill real-world experience; earlier EASD findings are separate and do not confirm ObesityWeek results.

1 stocks
NVONovo-Nordisk A/S$38.63Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

US President Trump is reportedly seriously considering resuming military strikes against Iran shortly after the US midterms if diplomacy fails, while the US remains engaged in negotiations over a temporary peace deal, Semafor reports

Geopolitics

Iran's IRGC Navy claims three tankers struck naval mines, exploded and caught fire while travelling through an unauthorised southern route of the Strait of Hormuz over the past 24 hours, with the vessels subsequently abandoned

U.S. Markets

[MARKET UPDATE] Alphabet (GOOGL) -10.6% and Microsoft (MSFT) +4% in the pre-market following results

GOOGLGOOGMSFT